First Effective Treatment for Long COVID
Researchers at Stanford University have announced results from a landmark clinical trial showing that the antiviral drug ensitrelvir, originally developed for acute COVID-19 treatment, achieves a 60% recovery rate when used to treat long COVID. The findings, published in Nature Medicine, represent the most significant therapeutic breakthrough for long COVID since the condition was first recognized in 2020.
The trial offers hope to the estimated 65 million people worldwide who continue to suffer from persistent symptoms months or years after their initial COVID-19 infection, many of whom have been unable to return to normal daily activities.
Trial Design and Results
The randomized, double-blind, placebo-controlled trial enrolled 1,200 patients with confirmed long COVID of at least six months duration. Participants received either a 15-day course of ensitrelvir or placebo, with follow-up assessments at 30, 60, and 90 days after treatment completion.
- Primary endpoint: 60.3% of patients in the treatment group reported meaningful improvement or complete resolution of their primary symptoms, compared to 18.7% in the placebo group.
- Fatigue: The most common long COVID symptom, fatigue, improved in 67% of treated patients.
- Brain fog: Cognitive symptoms improved in 54% of treated patients, with measurable gains on standardized neuropsychological tests.
- Exercise tolerance: Patients showed an average 28% improvement in exercise capacity as measured by the 6-minute walk test.
- Sustained benefit: At 90 days post-treatment, 85% of initial responders maintained their improvement, suggesting durable benefit.
How It Works
The mechanism behind ensitrelvir's effectiveness in long COVID appears to involve the elimination of persistent viral reservoirs in the body. Growing evidence suggests that long COVID is driven, at least in part, by fragments of SARS-CoV-2 that persist in various tissues long after the acute infection has resolved. These viral remnants trigger ongoing immune activation and inflammation that produce the chronic symptoms characteristic of long COVID.
"Our findings strongly support the viral persistence hypothesis of long COVID. By targeting and eliminating residual virus with an extended course of antiviral therapy, we are able to break the cycle of chronic immune activation that drives symptoms." - Dr. Upinder Singh, Stanford University
Patient Impact
For the millions of people living with long COVID, the trial results offer the first real pharmaceutical hope. Many patients have been told there is no treatment for their condition and have resorted to a patchwork of symptom management strategies with limited effectiveness. The prospect of an evidence-based treatment that addresses the underlying cause of their symptoms is generating enormous interest in the patient community.
Long COVID support groups report being inundated with inquiries since the trial results were published. Patient advocates are calling for expedited regulatory review and immediate expansion of treatment access through compassionate use programs.
Regulatory and Access Pathway
Ensitrelvir is already approved in Japan for acute COVID-19 treatment, and the manufacturer Shionogi is preparing an FDA supplemental application for the long COVID indication. The company has indicated it will seek priority review status given the significant unmet medical need.
If approved, the treatment would cost approximately $1,200 for a full 15-day course, a price point that has drawn criticism from patient advocacy groups who argue it should be more affordable given the scale of the long COVID population. Insurance coverage will be a critical factor in ensuring broad access to the treatment.
Remaining Questions
While the results are highly encouraging, researchers acknowledge that important questions remain. The trial did not include patients with long COVID of less than six months duration, and it is unclear whether earlier treatment would be more or less effective. Additionally, the 40% of patients who did not respond to treatment may have different underlying mechanisms driving their symptoms, suggesting that long COVID may encompass multiple distinct conditions requiring different therapeutic approaches.
